The decision was made after a recently conducted independent futility analysis concluded HBBN, the second of Lilly’s two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion.
The recently completed phase II study HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, also failed to meet its primary endpoint.
Lilly is contacting study investigators to outline specific actions related to the close-out of each ongoing study.
Lilly will work with study investigators to ensure an appropriate transition of study participants to continuing clinical care outside of the trials.
Lilly Research Laboratories president and science and technology executive vice president Jan Lundberg said he is disappointed in what the results mean for patients with schizophrenia who still are searching for options to treat it.
"While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly,” Lundberg added.
”Our clinical development pipeline includes nearly a dozen neuroscience molecules being studied to treat illnesses such as depression, bipolar disorder and cognitive impairment associated with schizophrenia."